Major U.S. pharmaceutical company Johnson & Johnson said Friday that its single-dose experimental vaccine was 66 percent effective in preventing the disease caused by the novel coronavirus in a late-stage global clinical trial.The company intends to file for emergency use authorization in the United States in early February and have the product available to ship immediately following authorization, according to its press release.In the trial joined by about 44,000 participants, the level of protection against moderate to severe COVID-19 infection 28 days after vaccination was 72 percent in …READ FULL ARTICLE
